Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EWO1
- Development stage
- Unknown
- Lead developer
- China Medical University Hospital
01
Overview
EWO1 is an investigational therapeutic initially developed by China Medical University Hospital. It has been studied primarily for immune system diseases, infectious diseases, and otorhinolaryngologic diseases, with a particular focus on perennial allergic rhinitis (persistent allergic rhinitis). The drug reached Phase 2/3 clinical trials in Taiwan for this indication. While the precise mechanism of action and molecular modality are not publicly disclosed, available information suggests it may be related to traditional Chinese medicine formulations used for allergic conditions[1][3]. No further details about its pharmacology or active ingredients are available in public sources.
- Other names
- EWO1EWO-1EWO 1
Beyond the preview
Go deeper on EWO1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EWO1.